NasdaqGS:CGONBiotechs
CG Oncology (CGON) Valuation Check As Bladder Cancer Trial Timelines Accelerate And Cash Runway Extends To 2029
CG Oncology (CGON) has drawn fresh attention after updating timelines for topline data from key Phase 2 and Phase 3 bladder cancer trials, while also highlighting a cash runway that management expects will extend into 2029.
See our latest analysis for CG Oncology.
The recent update on expedited trial timelines and a cash runway into 2029 comes after a strong run in the shares, with the latest close at $58.8, a 90 day share price return of 42.13% and a 1 year total shareholder return of...